Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease.
Yamakawa H, Sato S, Ohta H, Kusano K, Kawabe R, Oba T, Uzuka C, Sasaki H, Akasaka K, Amano M, Takemura T, Araya J, Matsushima H. Yamakawa H, et al. Among authors: kusano k. Respir Investig. 2024 Apr 24;62(4):551-557. doi: 10.1016/j.resinv.2024.04.011. Online ahead of print. Respir Investig. 2024. PMID: 38663299
Levetiracetam-induced interstitial lung disease in a patient with advanced lung cancer.
Sato S, Oba T, Ohta H, Tsukahara Y, Kida G, Tsumiyama E, Kusano K, Nishizawa T, Kawabe R, Yamakawa H, Akasaka K, Amano M, Matsushima H. Sato S, et al. Among authors: kusano k. Respir Med Case Rep. 2020 Sep 28;31:101241. doi: 10.1016/j.rmcr.2020.101241. eCollection 2020. Respir Med Case Rep. 2020. PMID: 33024691 Free PMC article.
Nivolumab-induced contact dermatitis in a patient with advanced lung cancer.
Sato S, Oba T, Ohta H, Tsukahara Y, Kida G, Tsumiyama E, Kusano K, Nishizawa T, Kawabe R, Yamakawa H, Akasaka K, Amano M, Matsushima H. Sato S, et al. Among authors: kusano k. Respir Med Case Rep. 2020 Jun 15;30:101134. doi: 10.1016/j.rmcr.2020.101134. eCollection 2020. Respir Med Case Rep. 2020. PMID: 32577373 Free PMC article.
A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.
Kaneko N, Loughrey CM, Smith G, Matsuda R, Hasunuma T, Mark PB, Toda M, Shinozaki M, Otani N, Kayley S, Da Silva Costa A, Martin TP, Dobi S, Saxena P, Shimamoto K, Ishikawa T, Kambayashi R, Riddell A, Elliott EB, McCarroll CS, Sakai T, Mitsuhisa Y, Hirano S, Kitai T, Kusano K, Inoue Y, Nakamura M, Kikuchi M, Toyoda S, Taguchi I, Fujiwara T, Sugiyama A, Kumagai Y, Iwata K. Kaneko N, et al. Among authors: kusano k. Br J Pharmacol. 2024 May 21. doi: 10.1111/bph.16379. Online ahead of print. Br J Pharmacol. 2024. PMID: 38773354
Global LEADR pivotal trial results.
Crossley GH, Sanders P, Hansky B, De Filippo P, Shah MJ, Shoda M, Khelae SK, Richardson T, Philippon F, Zakaib JS, Tse HF, Sholevar DP, Stellbrink C, Pathak RK, Milašinović G, Chinitz JS, Tsang B, West MB, Ramza BM, Han X, Bozorgnia B, Carta R, Geelen T, Himes A, Platner M, Thompson AE, Mason P; Lead EvaluAtion for Defibrillation and Reliability Trial Investigators. Crossley GH, et al. Heart Rhythm. 2024 May 7:S1547-5271(24)02395-6. doi: 10.1016/j.hrthm.2024.04.067. Online ahead of print. Heart Rhythm. 2024. PMID: 38762820 Free article.
896 results